Free & confidential case reviews · No obligation (877) 342-6154

Home / Cases / Zantac

Prescription DrugLimited intake

Zantac (Ranitidine) Cancer Lawsuit

Took Zantac or ranitidine regularly and later diagnosed with cancer? Find out if you qualify.

StatusLimited intake
Case typePrescription Drug
Case reviewFree & confidential
Last updatedNovember 2026

About this case

In April 2020 the FDA asked manufacturers to pull ranitidine (Zantac) from the market after finding unacceptable levels of NDMA, a probable carcinogen. Lawsuits claim long-term use led to certain cancers.

Where the case stands

This litigation has had major setbacks: the federal cases were dismissed (an appeal is pending) and a Delaware court dismissed tens of thousands of state cases in April 2026, while GSK and other manufacturers settled many claims. Intake is limited, so a reviewer will confirm whether your claim can still be pursued.

Status last reviewed November 2026. Lawsuit developments change often.

Who may qualify

  • You took Zantac or generic ranitidine regularly (generally at least weekly for a year)
  • You were later diagnosed with a qualifying cancer
  • Your claim is within your state's filing deadline

Injuries and conditions involved

Bladder cancerStomach (gastric) cancerEsophageal cancerLiver cancerPancreatic cancer
Do not stop taking any prescribed medication without first consulting your doctor.

Free · Confidential · About 2 minutes

Find out if you qualify

Answer a few quick questions about your Zantac claim. There's no cost and no obligation.

See If I Qualify

Prefer to talk? Call (877) 342-6154

Free Case Review